3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
7
Phase 4
2
Phase 2
2
Phase 1
1
Status
Completed
2
Sponsor Class
OTHER
4
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Endocrine
2
NET
1
Conditions
Neuroendocrine Tumour With Carcinoid Symptoms
1
Neuroendocrine Tumors
1
Interventions
Zoledronic Acid
23
Bevacizumab
13
nilotinib
12
Docetaxel
12
Paclitaxel
11
Everolimus
11
Letrozole
10
Imatinib Mesylate
10
Capecitabine
10
Erlotinib Hydrochloride
9
Drug Therapy
9
Carboplatin
9
pegfilgrastim
8
enzalutamide
8
Trastuzumab
7
Oxycodone
7
Nivolumab
7
Imiquimod
7
Gemcitabine
7
Epoetin Alfa
7
icotinib
6
Rituximab
6
Prednisone
6
Pemetrexed
6
Oxaliplatin
6
Leuprolide
6
Fulvestrant
6
Diclofenac
6
Dexamethasone
6
Cisplatin
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 4
×
INDUSTRY
×
lanreotide
×
Clear all
NCT00681187
2019-11-22
SAPHE
Ipsen
Phase 4
Completed
26 enrolled
18 charts
NCT02075606
2019-06-07
CALM-NET
Ipsen
Phase 4
Completed
50 enrolled
12 charts